BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 26733416)

  • 21. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.
    Xie Y; Tan Y; Zheng Y; Du X; Liu Q
    J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased neuronal PreP activity reduces Aβ accumulation, attenuates neuroinflammation and improves mitochondrial and synaptic function in Alzheimer disease's mouse model.
    Fang D; Wang Y; Zhang Z; Du H; Yan S; Sun Q; Zhong C; Wu L; Vangavaragu JR; Yan S; Hu G; Guo L; Rabinowitz M; Glaser E; Arancio O; Sosunov AA; McKhann GM; Chen JX; Yan SS
    Hum Mol Genet; 2015 Sep; 24(18):5198-210. PubMed ID: 26123488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hippocampal administration of chondroitinase ABC increases plaque-adjacent synaptic marker and diminishes amyloid burden in aged APPswe/PS1dE9 mice.
    Howell MD; Bailey LA; Cozart MA; Gannon BM; Gottschall PE
    Acta Neuropathol Commun; 2015 Sep; 3():54. PubMed ID: 26337292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer's disease.
    Shao CY; Mirra SS; Sait HB; Sacktor TC; Sigurdsson EM
    Acta Neuropathol; 2011 Sep; 122(3):285-92. PubMed ID: 21630115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ.
    Ittner A; Asih PR; Tan ARP; Prikas E; Bertz J; Stefanoska K; Lin Y; Volkerling AM; Ke YD; Delerue F; Ittner LM
    Acta Neuropathol; 2020 Sep; 140(3):279-294. PubMed ID: 32725265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synaptic Compensation as a Probable Cause of Prolonged Mild Cognitive Impairment in Alzheimer's Disease: Implications from a Transgenic Mouse Model of the Disease.
    Baazaoui N; Flory M; Iqbal K
    J Alzheimers Dis; 2017; 56(4):1385-1401. PubMed ID: 28222506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's Disease Risk Factor Pyk2 Mediates Amyloid-β-Induced Synaptic Dysfunction and Loss.
    Salazar SV; Cox TO; Lee S; Brody AH; Chyung AS; Haas LT; Strittmatter SM
    J Neurosci; 2019 Jan; 39(4):758-772. PubMed ID: 30518596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxic amyloid-β oligomers induced self-replication in astrocytes triggering neuronal injury.
    Wang W; Hou TT; Jia LF; Wu QQ; Quan MN; Jia JP
    EBioMedicine; 2019 Apr; 42():174-187. PubMed ID: 30926423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sulforaphene, a CDK5 Inhibitor, attenuates cognitive deficits in a transgenic mouse model of Alzheimer's disease via reducing Aβ Deposition, tau hyperphosphorylation and synaptic dysfunction.
    Yang W; Xu QQ; Yuan Q; Xian YF; Lin ZX
    Int Immunopharmacol; 2023 Jan; 114():109504. PubMed ID: 36508924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tau and Amyloid β Protein in Patient-Derived Aqueous Brain Extracts Act Concomitantly to Disrupt Long-Term Potentiation
    Ondrejcak T; Klyubin I; Hu NW; O'Malley TT; Corbett GT; Winters R; Perkinton MS; Billinton A; Prenderville JA; Walsh DM; Rowan MJ
    J Neurosci; 2023 Aug; 43(32):5870-5879. PubMed ID: 37491315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer's disease without reducing amyloid and tau pathology.
    Isopi E; Granzotto A; Corona C; Bomba M; Ciavardelli D; Curcio M; Canzoniero LM; Navarra R; Lattanzio R; Piantelli M; Sensi SL
    Neurobiol Dis; 2015 Sep; 81():214-24. PubMed ID: 25434488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo.
    Tomiyama T; Matsuyama S; Iso H; Umeda T; Takuma H; Ohnishi K; Ishibashi K; Teraoka R; Sakama N; Yamashita T; Nishitsuji K; Ito K; Shimada H; Lambert MP; Klein WL; Mori H
    J Neurosci; 2010 Apr; 30(14):4845-56. PubMed ID: 20371804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term modern life-like stress exacerbates Aβ-pathology and synapse loss in 3xTg-AD mice.
    Baglietto-Vargas D; Chen Y; Suh D; Ager RR; Rodriguez-Ortiz CJ; Medeiros R; Myczek K; Green KN; Baram TZ; LaFerla FM
    J Neurochem; 2015 Sep; 134(5):915-26. PubMed ID: 26077803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer's transgenic mice.
    Dobarro M; Gerenu G; Ramírez MJ
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2245-57. PubMed ID: 23768694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accelerated tau pathology with synaptic and neuronal loss in a novel triple transgenic mouse model of Alzheimer's disease.
    Saul A; Sprenger F; Bayer TA; Wirths O
    Neurobiol Aging; 2013 Nov; 34(11):2564-73. PubMed ID: 23747045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
    PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory.
    Fá M; Puzzo D; Piacentini R; Staniszewski A; Zhang H; Baltrons MA; Li Puma DD; Chatterjee I; Li J; Saeed F; Berman HL; Ripoli C; Gulisano W; Gonzalez J; Tian H; Costa JA; Lopez P; Davidowitz E; Yu WH; Haroutunian V; Brown LM; Palmeri A; Sigurdsson EM; Duff KE; Teich AF; Honig LS; Sierks M; Moe JG; D'Adamio L; Grassi C; Kanaan NM; Fraser PE; Arancio O
    Sci Rep; 2016 Jan; 6():19393. PubMed ID: 26786552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic low dose of AM404 ameliorates the cognitive impairment and pathological features in hyperglycemic 3xTg-AD mice.
    Huang HJ; Chen SL; Huang HY; Sun YC; Lee GC; Lee-Chen GJ; Hsieh-Li HM; Su MT
    Psychopharmacology (Berl); 2019 Feb; 236(2):763-773. PubMed ID: 30426182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines.
    Yu W; Polepalli J; Wagh D; Rajadas J; Malenka R; Lu B
    Hum Mol Genet; 2012 Mar; 21(6):1384-90. PubMed ID: 22156579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Over-expression of miR-34a induces rapid cognitive impairment and Alzheimer's disease-like pathology.
    Sarkar S; Engler-Chiurazzi EB; Cavendish JZ; Povroznik JM; Russell AE; Quintana DD; Mathers PH; Simpkins JW
    Brain Res; 2019 Oct; 1721():146327. PubMed ID: 31295467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.